{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:02:09Z","timestamp":1791190929154,"version":"4.1.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.prostaglandins.2015.04.007","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T15:13:40Z","timestamp":1429974820000},"page":"56-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors"],"prefix":"10.1016","volume":"120","author":[{"given":"Lucie H.","family":"Clapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rijan","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1000","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Inter Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0735-1097(94)00391-3","article-title":"Primary pulmonary hypertension in children: clinical characterization and survival","volume":"25","author":"Sandoval","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/2045-8932.114752","article-title":"Signal transduction in the development of pulmonary arterial hypertension","volume":"3","author":"Malenfant","year":"2013","journal-title":"Pulm Circ"},{"issue":"Suppl. 2","key":"10.1016\/j.prostaglandins.2015.04.007_bib1020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2362.2009.02120.x","article-title":"The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies","volume":"39","author":"Davie","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1025","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1030","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1035","doi-asserted-by":"crossref","first-page":"L1202","DOI":"10.1152\/ajplung.00214.2006","article-title":"Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry","volume":"292","author":"Zhang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1040","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1045","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/hc3201.094152","article-title":"Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-\u03b21 and bone morphogenetic proteins","volume":"104","author":"Morrell","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1165\/rcmb.2012-0049OC","article-title":"Inhibition of overactive transforming growth factor-\u03b2 signaling by prostacyclin analogs in pulmonary arterial hypertension","volume":"48","author":"Ogo","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1055","doi-asserted-by":"crossref","first-page":"L1059","DOI":"10.1152\/ajplung.90611.2008","article-title":"Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall","volume":"297","author":"Frid","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1060","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: The hope for etiologic discovery and pharmacologic cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1065","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1472-8206.2006.00425.x","article-title":"Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?","volume":"20","author":"Becker","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1080","first-page":"389","article-title":"Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension","volume":"146","author":"Chazova","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1085","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/PCC.0b013e3181c76db3","article-title":"Emerging therapies for the treatment of pulmonary hypertension","volume":"11","author":"Stenmark","year":"2010","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1164\/rccm.201308-1543PP","article-title":"Novel and emerging therapies for pulmonary hypertension","volume":"189","author":"Pullamsetti","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1095","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1100","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/VHRM.S2477","article-title":"Treprostinil for pulmonary hypertension","volume":"4","author":"Skoro-Sajer","year":"2008","journal-title":"Vasc Health Risk Manage"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1115","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.healun.2012.02.025","article-title":"Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension","volume":"31","author":"Sadushi-Kolici","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1120","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2466-11-56","article-title":"Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy","volume":"11","author":"Knudsen","year":"2011","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1130","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1135","first-page":"27","article-title":"The mechanistic basis for prostacyclin action in pulmonary hypertension","author":"Clapp","year":"2010","journal-title":"Int J Respir Care"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2013.07.003","article-title":"Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins","volume":"106","author":"Orie","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":"Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Molec Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1155","first-page":"342","article-title":"The case for treatment of selected patients with primary pulmonary hypertension","volume":"134","author":"Reeves","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1160","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1165","first-page":"321","article-title":"Pulmonary hypertension \u2013 beyond vasodilator therapy","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1170","doi-asserted-by":"crossref","first-page":"78S","DOI":"10.1378\/chest.126.1_suppl.78S","article-title":"Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McLaughlin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.intimp.2004.10.016","article-title":"Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs","volume":"5","author":"Zardi","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1180","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1253\/circj.CJ-10-0195","article-title":"Prostacyclin in vascular diseases \u2013 recent insights and future perspectives","volume":"74","author":"Kawabe","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1185","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.RES.0000126050.41296.8E","article-title":"Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3\/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension","volume":"94","author":"Schermuly","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCRESAHA.109.209940","article-title":"Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo","volume":"107","author":"Yang","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1195","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1172\/JCI33452","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"118","author":"Rabinovitch","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2008.10.002","article-title":"Therapeutic targets in pulmonary arterial hypertension","volume":"121","author":"Rhodes","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"Suppl. 58","key":"10.1016\/j.prostaglandins.2015.04.007_bib1205","first-page":"P2355","article-title":"Comparison of current therapies to inhibit endothelin-induced growth of pulmonary artery smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension","volume":"44","author":"Patel","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1183\/09031936.00167010","article-title":"Endothelin receptor expression in IPAH: effect of bosentan and epoprostenol treatment","volume":"38","author":"Hall","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","article-title":"Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling","volume":"25","author":"Wort","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1225","doi-asserted-by":"crossref","first-page":"L984","DOI":"10.1152\/ajplung.00224.2003","article-title":"Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase","volume":"286","author":"Kelly","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1230","first-page":"3","article-title":"Prostacyclin among prostanoids","volume":"60","author":"Gryglewski","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-6980(94)90060-4","article-title":"Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets","volume":"47","author":"Jakubowski","year":"1994","journal-title":"Prostaglandins"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1240","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structure, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1245","doi-asserted-by":"crossref","first-page":"L103","DOI":"10.1152\/ajplung.00095.2004","article-title":"cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling","volume":"288","author":"Phillips","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1250","doi-asserted-by":"crossref","first-page":"L294","DOI":"10.1152\/ajplung.00190.2006","article-title":"Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1","volume":"292","author":"Murray","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1255","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1465-9921-8-4","article-title":"Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs","volume":"8","author":"Schermuly","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1260","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor","volume":"388","author":"Murata","year":"1997","journal-title":"Nature (London)"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1270","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/hrt.57.3.270","article-title":"Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)","volume":"57","author":"Jones","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1275","first-page":"539","article-title":"Effects of prostacyclin in atherosclerotic vascular disease","volume":"15","author":"Gryglewski","year":"1985","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1280","series-title":"Prostacyclin: new prospectives for basic research and novel therapeutic indications","first-page":"169","article-title":"Prostacyclin and atherosclerosis","author":"Fredrich","year":"1992"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.ATV.19.3.727","article-title":"Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury","volume":"19","author":"Numaguchi","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.STR.30.2.419","article-title":"Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats","volume":"30","author":"Todaka","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1295","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1006\/bbrc.1995.2701","article-title":"Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells","volume":"216","author":"Hara","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1300","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1161\/01.CIR.0000034733.93020.BC","article-title":"Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction","volume":"106","author":"Yokoyama","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1305","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1126\/science.1103333","article-title":"COX-2-derived prostacyclin confers atheroprotection on female mice","volume":"306","author":"Egan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1310","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1172\/JCI200421446","article-title":"Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice","volume":"114","author":"Kobayashi","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1315","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1164\/ajrccm.164.2.2010150","article-title":"Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling","volume":"164","author":"Hoshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1320","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.104.527077","article-title":"Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor","volume":"112","author":"Hara","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1325","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cmet.2005.08.005","article-title":"Prostacyclin protects against elevated blood pressure and cardiac fibrosis","volume":"2","author":"Francois","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1330","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/ATVBAHA.109.193730","article-title":"Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling","volume":"30","author":"Kawabe","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1335","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1253\/circj.CJ-12-0897","article-title":"Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic hind limb model","volume":"77","author":"Aburakawa","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1340","series-title":"Progress in medical chemistry","first-page":"237","article-title":"Antithrombotic assessment and clinical potential of prostacyclin analogues","author":"Whittle","year":"1984"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1345","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00005344-199311000-00007","article-title":"Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers","volume":"22","author":"Demolis","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1355","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0091270004264638","article-title":"Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1360","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2013.07.001","article-title":"A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor","volume":"107","author":"Benyahia","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1365","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.2014.876007","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"15","author":"Skoro-Sajer","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1370","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1375","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.112.197152","article-title":"Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery","volume":"343","author":"Morrison","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1385","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0090-6980(82)90036-3","article-title":"Studies on the characterisation of prostanoid receptors: a proposed classification","volume":"24","author":"Kennedy","year":"1982","journal-title":"Prostaglandins"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1390","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1476-5381.1992.tb14245.x","article-title":"Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum","volume":"105","author":"Lawrence","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1395","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1476-5381.1982.tb09336.x","article-title":"Pinane thromboxane A2 analogues are non-selective prostanoid antagonists in rat and human stomach muscle","volume":"77","author":"Bennett","year":"1982","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1400","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1021\/ac025518v","article-title":"Determination of prostacyclin in plasma through a bioluminescent immunoassay for 6-keto-prostaglandin F1\u03b1: implication of dosage in patients with primary pulmonary hypertension","volume":"74","author":"Desai","year":"2002","journal-title":"Anal Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1405","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1100\/tsw.2007.184","article-title":"Prostanoid receptors in the human vascular wall","volume":"7","author":"Norel","year":"2007","journal-title":"Sci World J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1410","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1415","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cardiores.2005.08.004","article-title":"Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism","volume":"69","author":"Orie","year":"2006","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1425","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejphar.2010.12.005","article-title":"Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: evidence for Gi\/o modulation via EP3 receptors","volume":"654","author":"Orie","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1430","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1161\/ATVBAHA.112.300536","article-title":"Heterodimerization with the prostacyclin receptor triggers thromboxane receptor relocation to lipid rafts","volume":"33","author":"Ibrahim","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1435","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/CIRCULATIONAHA.106.663120","article-title":"Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-\u03b3 activation","volume":"115","author":"Hansmann","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1388-1981(99)00164-X","article-title":"The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs","volume":"1483","author":"Abramovitz","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1445","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(98)00549-4","article-title":"Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost","volume":"356","author":"Clapp","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1450","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/CIRCULATIONAHA.106.676809","article-title":"Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy","volume":"115","author":"Schermuly","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1455","doi-asserted-by":"crossref","first-page":"G1078","DOI":"10.1152\/ajpgi.00524.2009","article-title":"Roles of prostaglandin E2-EP1 receptor signaling in regulation of gastric motor activity and emptying","volume":"299","author":"Mizuguchi","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1460","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.200710-1519OC","article-title":"Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension","volume":"178","author":"Lai","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00614197","article-title":"Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man","volume":"30","author":"Krause","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1470","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","article-title":"Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities","volume":"178","author":"Aronoff","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1475","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.plefa.2014.11.011","article-title":"Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP1 activity","volume":"95","author":"Syed","year":"2015","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1480","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0091270007309708","article-title":"Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion","volume":"48","author":"McSwain","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1485","doi-asserted-by":"crossref","first-page":"L213","DOI":"10.1152\/ajplung.00103.2004","article-title":"Role of veins in regulation of pulmonary circulation","volume":"288","author":"Gao","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1490","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjp.0702392","article-title":"Prostanoid receptors involved in the relaxation of human bronchial preparations","volume":"126","author":"Norel","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1495","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pupt.2011.12.012","article-title":"PGE2 receptor (EP4) agonists: potent dilators of human bronchi and future asthma therapy","volume":"25","author":"Benyahia","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1500","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.110.174821","article-title":"Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors","volume":"336","author":"Petrucci","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1505","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2014.06.030","article-title":"Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors","volume":"740","author":"Hubertus","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1510","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1096\/fj.05-4395fje","article-title":"Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR\u03b2","volume":"20","author":"Ali","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1515","doi-asserted-by":"crossref","first-page":"L405","DOI":"10.1152\/ajplung.00232.2006","article-title":"Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling","volume":"292","author":"Huang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2011.03.001","article-title":"Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca2+ concentrations in human airway smooth muscle cells","volume":"659","author":"Mori","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1525","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/ATVBAHA.111.226142","article-title":"Targeted disruption of the prostaglandin E2 E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice","volume":"31","author":"Zhu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1530","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2004-0126OC","article-title":"Prostaglandin E2 inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity","volume":"32","author":"White","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1535","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1165\/rcmb.2002-0243OC","article-title":"Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation","volume":"29","author":"Kolodsick","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1540","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.4049\/jimmunol.174.9.5644","article-title":"Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2","volume":"174","author":"Moore","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1545","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"Kuwano","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1550","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.110.169748","article-title":"Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function","volume":"335","author":"Morrison","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1555","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1476-5381.2010.01039.x","article-title":"Interaction of prostanoid EP3 and TP receptors in guinea-pig isolated aorta: contractile self-synergism of 11-deoxy-16,16-dimethyl PGE2","volume":"162","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1560","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1152\/jappl.1996.81.6.2595","article-title":"Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors","volume":"81","author":"Zhao","year":"1996","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1565","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/S0021-9258(20)81984-X","article-title":"Bimodal distribution of the prostaglandin I2 synthase antigen in smooth muscle cells","volume":"258","author":"Smith","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1570","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1210\/en.2002-220159","article-title":"A novel pathway of prostacyclin signaling-hanging out with nuclear receptors","volume":"143","author":"Lim","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1575","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.tips.2012.05.005","article-title":"Vascular effects of prostacyclin: does activation of PPARdelta play a role","volume":"33","author":"Katusic","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1580","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR \u03b3","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1585","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","article-title":"Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta","volume":"94","author":"Forman","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1590","doi-asserted-by":"crossref","first-page":"31473","DOI":"10.1074\/jbc.M111.266023","article-title":"Structural basis for iloprost as a dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist","volume":"286","author":"Jin","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1595","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcp.21214","article-title":"Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells","volume":"214","author":"Lin","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1600","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.yjmcc.2003.10.016","article-title":"Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors","volume":"36","author":"Pola","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1605","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/1940-6207.CAPR-08-0145","article-title":"Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor \u03b3","volume":"1","author":"Nemenoff","year":"2008","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1610","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCRESAHA.108.176057","article-title":"Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells","volume":"103","author":"He","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1615","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/humrep\/dem304","article-title":"Prostacyclin receptor signaling and early embryo development in the mouse","volume":"22","author":"Huang","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1620","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bbrc.2007.06.135","article-title":"IP receptor-dependent activation of PPAR\u03b3 by stable prostacyclin analogues","volume":"360","author":"Falcetti","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1625","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1210\/mend.14.12.0575","article-title":"Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators","volume":"14","author":"Lazennec","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1630","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/ars.2008.2280","article-title":"PPARs and the cardiovascular system","volume":"11","author":"Hamblin","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1635","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1165\/rcmb.2012-0185OC","article-title":"Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPAR\u03b3 axis","volume":"49","author":"Wang","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1640","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0702383","article-title":"The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta","volume":"126","author":"Turcato","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1645","doi-asserted-by":"crossref","first-page":"18797","DOI":"10.1155\/2007\/18797","article-title":"The role of peroxisome proliferator-activated receptors in pulmonary vascular disease","volume":"2007","author":"Nisbet","year":"2007","journal-title":"PPAR Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1650","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1165\/rcmb.2010-0428OC","article-title":"Peroxisome proliferator-activated receptor-beta\/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation","volume":"46","author":"Li","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1655","doi-asserted-by":"crossref","first-page":"903947","DOI":"10.1155\/2013\/903947","article-title":"PPARdelta agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling","volume":"2013","author":"Liu","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1660","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/aps.2009.58","article-title":"The peroxisome proliferator-activated receptor-\u03b1 (PPAR-\u03b1) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats","volume":"30","author":"Linz","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1665","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/jpet.109.159806","article-title":"Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway","volume":"332","author":"Jimenez","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1670","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1165\/rcmb.2008-0132OC","article-title":"Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model","volume":"42","author":"Nisbet","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1675","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-013-0846-3","article-title":"Relaxation of human pulmonary arteries by PPAR\u03b3 agonists","volume":"386","author":"Kozlowska","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1680","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/2045-8932.78101","article-title":"Is peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) a therapeutic target for the treatment of pulmonary hypertension","volume":"1","author":"Green","year":"2011","journal-title":"Pulm Circ"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1685","doi-asserted-by":"crossref","first-page":"374075","DOI":"10.1155\/2014\/374075","article-title":"Rosiglitazone Attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors","volume":"2014","author":"Liu","year":"2014","journal-title":"PPAR Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1690","article-title":"Differential action of beraprost stereoisomers, iloprost and treprostinil in modulating vascular tone in rat arteries: Role of PPAR\u03b2 and prostanoid EP3 receptors","author":"Shen","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1695","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1164\/ajrccm.162.4.2003124","article-title":"Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy","volume":"162","author":"Eddahibi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1700","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000143793","article-title":"Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation","volume":"46","author":"Biscetti","year":"2009","journal-title":"J Vasc Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1705","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1165\/ajrcmb.17.6.2888","article-title":"Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP","volume":"17","author":"Hoper","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1710","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ijcard.2007.12.119","article-title":"Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells","volume":"132","author":"Atsuta","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1715","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.ATV.0000250972.83623.61","article-title":"Activation of PPAR\u03b2\/\u03b4 induces endothelial cell proliferation and angiogenesis","volume":"27","author":"Piqueras","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1720","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3892\/ijo.2013.1994","article-title":"VEGF expression is augmented by hypoxiainduced PGIS in human fibroblasts","volume":"43","author":"Wang","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1725","doi-asserted-by":"crossref","first-page":"25130","DOI":"10.1074\/jbc.274.35.25130","article-title":"Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1\/KDR activation of c-Src","volume":"274","author":"He","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1730","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/hc0602.103673","article-title":"Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration","volume":"105","author":"Iwaguro","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1735","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10456-010-9192-y","article-title":"Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension","volume":"14","author":"Smadja","year":"2011","journal-title":"Angiogenesis"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1740","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1160\/TH07-08-0509","article-title":"The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia","volume":"100","author":"Di","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1745","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s10016-005-7668-9","article-title":"The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study","volume":"19","author":"Murakami","year":"2005","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1750","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2310\/6670.2006.00028","article-title":"Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study","volume":"14","author":"Berman","year":"2006","journal-title":"Vascular"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1755","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00002281-199305060-00015","article-title":"Treatment of systemic sclerosis","volume":"5","author":"Pope","year":"1993","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1760","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2125.1993.tb04195.x","article-title":"Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers","volume":"35","author":"Belch","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1765","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2337\/db07-0765","article-title":"Selective activation of peroxisome proliferator-activated receptor (PPAR)\u03b1 and PPAR \u03b3 induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism","volume":"57","author":"Biscetti","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1770","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) expression is decreased in pulmonary hypertension and affects endothelial cell growth","volume":"92","author":"Ameshima","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1775","doi-asserted-by":"crossref","first-page":"L1082","DOI":"10.1152\/ajplung.00199.2009","article-title":"Tie2-mediated loss of peroxisome proliferator-activated receptor-\u03b3 in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization","volume":"297","author":"Guignabert","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1780","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCRESAHA.109.193656","article-title":"Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha\/delta activations by prostacyclin released by sheared endothelial cells","volume":"105","author":"Tsai","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1785","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1038\/emm.2013.112","article-title":"PPAR\u03b3 modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury","volume":"45","author":"Yang","year":"2013","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1790","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.yjmcc.2011.09.008","article-title":"Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype","volume":"52","author":"Ding","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1795","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1161\/01.CIR.102.25.3130","article-title":"Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells","volume":"102","author":"Wharton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1800","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/ATVBAHA.107.145011","article-title":"Inducible cAMP early repressor inhibits growth of vascular smooth muscle cell","volume":"27","author":"Ohtsubo","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1805","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/mol.64.2.249","article-title":"Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression","volume":"64","author":"Kothapalli","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1810","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1465-9921-8-77","article-title":"Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1","volume":"8","author":"Kadowaki","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1815","doi-asserted-by":"crossref","first-page":"C321","DOI":"10.1152\/ajpcell.00069.2009","article-title":"PPAR\u03b4-mediated p21\/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells","volume":"297","author":"Sue","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1820","doi-asserted-by":"crossref","first-page":"e98483","DOI":"10.1371\/journal.pone.0098483","article-title":"Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF beta-Smad signal pathway","volume":"9","author":"Chen","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1825","series-title":"Ion channels in the pulmonary vasculature","first-page":"257","article-title":"ATP-sensitive and inward rectifier K+ channels","author":"Clapp","year":"2005"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1830","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pharmthera.2014.08.001","article-title":"Ion channels and transporters as therapeutic targets in the pulmonary circulation","volume":"144","author":"Olschewski","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1835","doi-asserted-by":"crossref","first-page":"C2213","DOI":"10.1152\/ajpcell.00139.2005","article-title":"Nuclear translocation of calcineurin A\u03b2 but not calcineurin A\u03b1 by platelet-derived growth factor in rat aortic smooth muscle","volume":"292","author":"Jabr","year":"2007","journal-title":"Am J Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1840","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.1073\/pnas.0610467104","article-title":"The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted","volume":"104","author":"Bonnet","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1845","doi-asserted-by":"crossref","first-page":"34983","DOI":"10.1074\/jbc.M005498200","article-title":"Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes","volume":"276","author":"Morimoto","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1850","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1855","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2340\/00015555-0632","article-title":"Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations","volume":"89","author":"Rehberger","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1860","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/rcmb.2005-0289OC","article-title":"Role of prostacyclin versus peroxisome proliferator-activated receptor \u03b2 receptors in prostacyclin sensing by lung fibroblasts","volume":"34","author":"Ali","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1865","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1165\/rcmb.2008-0197OC","article-title":"Activation of peroxisome proliferator-activated receptor \u03b2\/\u03b4 induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha","volume":"40","author":"Han","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1870","doi-asserted-by":"crossref","first-page":"e9526","DOI":"10.1371\/journal.pone.0009526","article-title":"The PPAR\u03b2\/\u03b4 agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension","volume":"5","author":"Harrington","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1875","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1880","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.CIR.88.5.2117","article-title":"Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease","volume":"88","author":"Adatia","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1885","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/ajmg.a.33555","article-title":"Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: an imbalance in biosynthesis of thromboxane A2 and prostacyclin","volume":"152A","author":"Fukushima","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1890","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1895","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/pr.2014.209","article-title":"Altered prostanoid metabolism contributes to impaired angiogenesis in persistent pulmonary hypertension in a fetal lamb model","volume":"77","author":"Mahajan","year":"2015","journal-title":"Pediatr Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1900","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI5911","article-title":"Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension","volume":"103","author":"Geraci","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1905","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/01.CIR.102.16.2005","article-title":"Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1910","doi-asserted-by":"crossref","first-page":"L615","DOI":"10.1152\/ajplung.00224.2010","article-title":"PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression","volume":"301","author":"Zhou","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1915","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1164\/rccm.201309-1697OC","article-title":"Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension","volume":"189","author":"Stearman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1920","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/ATVBAHA.110.208900","article-title":"Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease","volume":"30","author":"Ibrahim","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1925","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1930","doi-asserted-by":"crossref","first-page":"26238","DOI":"10.1074\/jbc.M110.214155","article-title":"Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins","volume":"286","author":"Begum","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1935","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1535370214547155","article-title":"Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension","volume":"240","author":"Bowles","year":"2015","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1940","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jvca.2014.06.012","article-title":"Preliminary experience with combined inhaled milrinone and prostacyclin in cardiac surgical patients with pulmonary hypertension","volume":"29","author":"Laflamme","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1945","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.avsg.2014.02.018","article-title":"Effects of cilostazol on arterial wound healing: a retrospective analysis","volume":"28","author":"Resnick","year":"2014","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1950","doi-asserted-by":"crossref","first-page":"e18136","DOI":"10.1371\/journal.pone.0018136","article-title":"Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling","volume":"6","author":"Tian","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1955","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.114.009751","article-title":"Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension","author":"Bubb","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1960","doi-asserted-by":"crossref","first-page":"23258","DOI":"10.1074\/jbc.273.36.23258","article-title":"Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c","volume":"273","author":"Smyth","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1965","doi-asserted-by":"crossref","first-page":"L352","DOI":"10.1152\/ajplung.00270.2003","article-title":"Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase","volume":"287","author":"Sobolewski","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1970","doi-asserted-by":"crossref","first-page":"20412","DOI":"10.1074\/jbc.M907881199","article-title":"The \u03b1, but not the \u03b2, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization","volume":"275","author":"Walsh","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1975","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.21432","article-title":"Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators","volume":"52","author":"Kowal-Bielecka","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1980","doi-asserted-by":"crossref","first-page":"32648","DOI":"10.1074\/jbc.M104143200","article-title":"Arrestin specificity for G protein-coupled receptors in human airway smooth muscle","volume":"276","author":"Penn","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1985","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1074\/jbc.M113.536805","article-title":"Down-regulated peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) in lung epithelial cells promotes a PPAR\u03b3 agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD)","volume":"289","author":"Lakshmi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1990","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.freeradbiomed.2013.05.013","article-title":"Hypoxia downregulates PPAR\u03b3 via an ERK1\/2-NF-kappaB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells","volume":"63","author":"Lu","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib1995","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPAR\u03b3\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2000","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1164\/ajrccm.164.8.2101070","article-title":"Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling","volume":"164","author":"Benayoun","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.imbio.2012.08.270","article-title":"Identification of novel markers of alternative activation and potential endogenous PPAR\u03b3 ligand production mechanisms in human IL-4 stimulated differentiating macrophages","volume":"217","author":"Czimmerer","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2010","doi-asserted-by":"crossref","first-page":"36031","DOI":"10.1074\/jbc.M114.600775","article-title":"Peroxisome proliferator-activated receptor-alpha-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1alpha","volume":"289","author":"Li","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MNH.0b013e328325803b","article-title":"PPARs: the vasculature, inflammation and hypertension","volume":"18","author":"Duan","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2020","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/CIRCRESAHA.108.173567","article-title":"Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension","volume":"102","author":"Yang","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.amjcard.2012.04.035","article-title":"Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers","volume":"110","author":"Chida","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/674755","article-title":"The peroxisome proliferator-activated receptor \u03b2\/\u03b4 agonist GW0742 has direct protective effects on right heart hypertrophy","volume":"3","author":"Kojonazarov","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2006.08.016","article-title":"Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension","volume":"549","author":"van Albada","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/thx.2008.106435","article-title":"Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children","volume":"64","author":"Hall","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.21187","article-title":"Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression","volume":"83","author":"Klings","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2050","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.102.22.2720","article-title":"Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy","volume":"102","author":"Sakamaki","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/meta.2003.50025","article-title":"Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus","volume":"52","author":"Goya","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1165\/ajrcmb\/3.4.301","article-title":"Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers","volume":"3","author":"Riva","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jaci.2009.12.002","article-title":"Endothelium-derived prostaglandin I2 controls the migration of eosinophils","volume":"125","author":"Konya","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1183\/09031936.00148311","article-title":"Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury","volume":"41","author":"Birukova","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2075","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/01.ATV.17.11.2568","article-title":"Regulation of tumor necrosis factor \u03b1- and interleukin-1-\u03b2-induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP","volume":"17","author":"Braun","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2080","doi-asserted-by":"crossref","first-page":"33344","DOI":"10.1074\/jbc.M203567200","article-title":"The prostacyclin analogue treprostinil blocks NF\u03baB nuclear translocation in human alveolar macrophages","volume":"277","author":"Raychaudhuri","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2085","article-title":"Effect of prostaglandin I analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage","author":"Tsai","year":"2014","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00011-011-0317-6","article-title":"Prostaglandin I2 analogues suppress TNF-\u03b1 expression in human monocytes via mitogen-activated protein kinase pathway","volume":"60","author":"Wang","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2095","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.178.2.702","article-title":"Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells","volume":"178","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1189\/jlb.0606375","article-title":"Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4T cells","volume":"81","author":"Zhou","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.plefa.2005.05.025","article-title":"Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6","volume":"73","author":"Di","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1253\/circj.68.227","article-title":"Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension","volume":"68","author":"Katsushi","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjp.0701367","article-title":"Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells","volume":"122","author":"Kiriyama","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1476-5381.1981.tb10994.x","article-title":"The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid","volume":"72","author":"Blair","year":"1981","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1983.tb01467.x","article-title":"Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects","volume":"15","author":"Shepherd","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.prostaglandins.2015.04.007_bib2130","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.bjp.0703525","article-title":"Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor","volume":"130","author":"Davis","year":"2000","journal-title":"Br J Pharmacol"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882315000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882315000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:54:42Z","timestamp":1651791282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882315000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":227,"alternative-id":["S1098882315000490"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.04.007","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}